cGxP.wire https://validator.w3.org/feed/docs/rss2.html Stoke Therapeutics and Biogen Present Zorevunersen Data at EEC MIRA Pharmaceuticals Advances MIRA-55 Toward Q1 2027 IND Novartis Remibrutinib Cuts Relapses in Phase III MS Trials AstraZeneca Tagrisso Combo Improves Lung Cancer PFS Intelligent Bio Solutions Reports 98.2% Accuracy in Drug Testing aTyr Pharma Awaits FDA Response on Efzofitimod Phase 3 Natera Validates Signatera for Lymphoma MRD Assessment Telix Completes BiPASS Enrollment and Aligns With FDA Resolution Therapeutics Expands U.S. Access for RTX001 Butterfly Network Partners With Merge Labs on Ultrasound BCI Guardant Health Expands Shield CRC Screening Coverage Ascendis, BioMarin Reach Global YUVIWEL License Deal XYRA Doses First European Patient in Budiodarone Trial Boehringer Launches First Horse Insulin Therapy Alumis Advances Envudeucitinib Toward Phase 3 in SLE Kyowa Kirin Reaches U.S. Agreement to Lower Medicine Costs GSK Advances mRNA Flu Vaccine to Phase III After Data Adicet Bio Advances Prula-Cel Toward SLE Data Readout Upstream Bio Sets Phase 3 Plans for Verekitug in Asthma AstraZeneca Completes Global Zegfrovy License Deal NeuroSense Advances PrimeC Toward Potential ALS Approval Fujirebio Expands Neurology Testing Access in Canada Astellas Reaches U.S. Agreement on Medicine Affordability Kymera Therapeutics Advances KT-621 in Atopic Dermatitis AAN, AHS Update Migraine Prevention Medication Guidelines AstraZeneca, Daiichi Sankyo Win EU Approval for Enhertu Ocugen Advances OCU410 into Phase 3 Gene Therapy Trial Enliven to Present Clinical Data at SOHO 2026 Meeting UCB Agreement Targets Medicine Costs and U.S. Manufacturing TTX-MC138 Shows Survival Benefit in Breast Cancer RedHill Advances Opaganib for Ebola Outbreak Response Veloxis Begins Phase 2 Trial of Pegrizeprument Eisai and Biogen Advance LEQEMBI Access in Canada PMV Pharma Reports 46% ORR in Ovarian Cancer Trial Teva Advances U.S. Deal on Affordable Medicines and Supply AN2 Therapeutics Highlights Epetraborole Data for PV at SOHO Arch Biopartners Gains U.S. IRB Approval for LSALT Phase II AIM ImmunoTech Wins U.S. Patent for Ampligen Cancer Therapy BridgeBio Expands U.S. Access to Rare Disease Medicines Lilly to Acquire Merida in $2.875B Immunology Deal BeOne Medicines Expands U.S. Cancer Access and Manufacturing Amarin Highlights New REDUCE-IT Data at ESC 2026 PharmaEssentia Wins FDA Approval for BESREMi in ET Karmanos Offers FDA-Approved Daraxonrasib for Cancer Lilly’s Taltz and Zepbound Show One-Year Benefits RedHill Divests Talicia to Apotex for $18 Million GE HealthCare Photonova Spectra Gains CE Mark for CT IDEAYA’s IDE849 Advances Toward Phase 3 in Lung Cancer Beyond Air Wins FDA Breakthrough Device Status for LungFit GO Amgen Shows Repatha Reduces Death Risk in High-Risk Patients